10 Best Biotech Stocks to Buy Under $10
The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC's "Squawk Box" on July 25 to discuss various topics, including the current status of the biotech industry and what to expect...
Novavax Inc (NVAX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 74,177,000 | $74,835,447 | 1.13% | ||
| 2. | Shah Capital Management Himanshu H. Shah | 11,511,780 | $72,524,214 | +4% | 14.11% |
| 3. | 27,750,000 | $27,455,156 | -10% | 0.58% | |
| 4. | D E Shaw D. E. Shaw | 3,940,960 | $24,828,048 | +21% | 0.02% |
| 5. | Coatue Management Philippe Laffont | 3,836,986 | $24,173,012 | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.50 | 1,000 | $6,500.00 | 14,473 | 2023-03-10 | Filing | |
| $7.04 | 2,000 | $14,088.00 | 13,473 | 2023-03-07 | Filing | |
| $7.48 | 3,000 | $22,453.50 | 11,473 | 2023-03-06 | Filing | |
| $139.64 | 700 | $97,748.00 | 2,800 | 2021-05-19 | Filing | |
| $48.83 | 1,500 | $73,245.00 | 1,500 | 2020-06-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.02 | 4,150 | $37,435.08 | 14,770 | 2024-12-13 | Filing | |
| $8.00 | 5,400 | $43,200.00 | 51,760 | 2024-12-31 | Filing | |
| $8.48 | 4,600 | $39,008.00 | 57,160 | 2024-12-24 | Filing | |
| $14.09 | 7,500 | $105,675.00 | 61,760 | 2024-06-21 | Filing | |
| $14.28 | 1,107 | $15,807.96 | 69,260 | 2024-06-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,433,212 | $97,229,236 | 0% | |
| 2. | 12,743,155 | $80,281,877 | 0% | |
| 3. | 6,880,481 | $43,347,030 | 24.67% | |
| 4. | 6,824,251 | $42,992,781 | 0% | |
| 5. | 3,768,353 | $23,743,709 | 0% |
News See All
Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership
Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and Matrix-M adjuvant technology.
11 Best Short Squeeze Stocks to Buy Now
The latest U.S. tariff wave has created a suitable environment where short squeeze investments will thrive.
Novavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Novavax Second Quarter 2025 Financial Results and Operational Highlights Conference Call. [Operator Instructions] Please note this event is being recorded.
13 Cheap Stocks with Huge Upside Potential
He stated that the episode of the last six months showed just how brutally efficient the price discovery process is, in any market but especially the US stock market.
Citi Initiates Coverage of Novavax (NVAX) With a Sell Rating
Novavax Inc. (NASDAQ:NVAX) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 17, Citi initiated coverage of Novavax Inc.
13 Cheap Healthcare Stocks with Huge Upside Potential
On July 8, Kate Moore, Citi Wealth CIO, appeared on CNBC's 'Squawk Box' to talk about the recent rally in equities.
BofA Reiterates Hold Rating on Novavax (NVAX) Stock
The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of 2025.
BTIG Maintains a Buy rating on Novavax (NVAX)
The approval marks a significant milestone for Novavax Inc. (NASDAQ:NVAX), aligning with the changing regulatory landscape after the pandemic.
JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News
On May 19, JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7.